Lumakras (Sotorasib) Market – Revolutionizing Non-Small Cell Lung Cancer Treatment

Lumakras (Sotorasib) Market – Revolutionizing Non-Small Cell Lung Cancer Treatment

 

According to Next Move Strategy Consulting, the global Lumakras (Sotorasib) Market is a breakthrough prescription drug primarily used for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has either spread to other parts of the body or cannot be removed through surgery. This novel medication specifically targets patients whose tumors have an abnormal KRAS G12C gene mutation. It works by blocking the action of the abnormal protein that signals cancer cells to multiply, ultimately slowing the cancer’s progression.

Approved by the Food and Drug Administration (FDA) in May 2021, Lumakras marked a significant milestone as the first treatment specifically targeting NSCLC with the KRAS G12C mutation. Developed by Amgen, this drug has opened new avenues in cancer treatment, offering hope to patients who previously had limited options.

Download Free Sample: https://www.nextmsc.com/lumakras-sotorasib-market/request-sample 

Market Overview:

The Lumakras market is expanding rapidly, driven by its efficacy in treating patients with a specific genetic mutation, KRAS G12C. The drug is available in tablet form and is generally prescribed to be taken once daily, before or after food. Lumakras has transformed the way NSCLC is treated, marking a paradigm shift in the field of cancer therapy.

The market for Lumakras is segmented based on various factors, including dosage, application, and geography. The available dosages of Lumakras include 960 mg, 480 mg, and 240 mg. In terms of application, it is used in hospitals, drug centers, clinics, and other healthcare settings. Geographically, the market is divided into regions such as North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Recent Developments:

In June 2021, Amgen launched a significant clinical combination study as part of the Phase 1b/2 CodeBreaK 101 program. The study focuses on patients with KRAS G12C-mutated advanced colorectal cancer (CRC), demonstrating promising efficacy and safety when combining Lumakras (Sotorasib) with Vectibix (panitumumab), an epidermal growth factor receptor (EGFR) inhibitor.

Moreover, in September 2021, Boehringer Ingelheim partnered with Amgen for a clinical Phase 1 collaboration. The focus of this collaboration is to assess the combination of BI 1701963, a pan-KRAS inhibitor, and Lumakras (Sotorasib). This collaboration aims to explore the potential of targeting a broader spectrum of KRAS mutations, showcasing the potential of Lumakras beyond lung cancer.

Inquire Before Buying: https://www.nextmsc.com/lumakras-sotorasib-market/inquire-before-buying 

Market Outlook:

The Lumakras market is expected to continue its growth trajectory, driven by increasing adoption of the drug in various regions, especially with the expanding clinical trials and ongoing research into new applications for the drug. Its success has sparked interest in new KRAS inhibitors, opening up exciting prospects in the treatment of various cancers beyond NSCLC.

Conclusion:

Lumakras (Sotorasib) represents a groundbreaking step in the treatment of NSCLC with a specific genetic mutation, offering new hope to patients previously left with limited treatment options. Its growing market presence, supported by clinical collaborations and research developments, positions it as a key player in the cancer treatment landscape. As more research and clinical studies explore its potential, Lumakras is expected to play an even more pivotal role in the fight against cancer.

Also, Browse Related Reports:   

For more information, please contact:

Next Move Strategy Consulting

E-Mail: info@nextmsc.com

Direct: +1-217-650-7991

Website: www.nextmsc.com

Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube

About Next Move Strategy Consulting: 

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

Back to blog